ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

IMMP Immutep Ltd

1.99
0.07 (3.65%)
Nov 30 2023 - Closed
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Immutep Ltd IMMP NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
0.07 3.65% 1.99 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.93 1.9064 2.01 1.99 1.92
more quote information »

Recent News

Date Time Source Heading
11/22/202308:00GLOBEImmutep Announces Site Expansion for INSIGHT-003 Phase I..
11/09/202308:00GLOBEImmutep Completes Enrollment in TACTI-003 Phase IIb Trial of..
11/06/202308:00GLOBEImmutep Announces Completion of the Safety Lead-In and..
11/03/202312:00GLOBEImmutep Announces New Biomarker Data from TACTI-002 Phase II..
11/03/202306:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/02/202308:00GLOBEImmutep to Participate in November Investor Events
10/31/202308:00GLOBEImmutep Quarterly Activities Report Q1 FY24
10/25/202308:00GLOBEImmutep receives ~A$1.13 million R&D Tax Incentive
10/25/202306:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/24/202308:00GLOBEImmutep Reports Promising Clinical Data from INSIGHT-003..
10/24/202306:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/23/202308:00GLOBEImmutep’s Efti in Combination with KEYTRUDA® Generates..
10/16/202308:00GLOBEImmutep Announces Publication of Abstracts at ESMO Congress..
10/03/202308:00GLOBEImmutep Announces Abstract Accepted for Presentation at the..
9/21/202308:00GLOBECommercial Manufacturing of Eftilagimod Alpha at 2000L Scale..
9/05/202309:00GLOBEImmutep to Participate in September Investor Conferences
8/01/202308:00GLOBEImmutep Receives Positive Scientific Advice from European..
7/31/202308:00GLOBEImmutep to Present Overall Survival Data in 1st Line..
7/28/202308:00GLOBEFirst Patient Dosed in Chemotherapy-Free Triple Combination..
7/28/202306:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
6/27/202308:00GLOBEImmutep Secures Third United States Patent for Eftilagimod..
6/20/202308:00GLOBEImmutep Granted United States Patent for IMP761, a..
6/07/202308:00GLOBEImmutep to Participate at the Jefferies Healthcare..
6/05/202308:00GLOBEImmutep Reports Final Positive Data in 2nd Line Head and..
6/02/202308:00GLOBEImmutep Successfully Completes Institutional Placement and..
5/29/202308:00GLOBEImmutep Selects Charles River Laboratories for IMP761’s GLP..
5/26/202308:00GLOBEImmutep Announces Publication of Abstracts for ASCO 2023..
5/25/202308:00GLOBEImmutep Doses First Patient in AIPAC-003 Phase II/III Trial..
5/24/202308:00GLOBEImmutep Announces Promising New Clinical Data from Triple..
5/17/202308:00GLOBEImmutep’s Efti in Combination with Pembrolizumab Achieves..
5/16/202308:00GLOBEImmutep Receives Positive Feedback from FDA on Late-Stage..
5/09/202308:00GLOBEImmutep to Participate in the JMP Securities Life Sciences..
5/02/202308:00GLOBEImmutep Announces KOL Event Focused on Eftilagimod Alpha in..
5/01/202308:00GLOBEImmutep Receives Approval to Initiate INSIGHT-005 Trial..
4/27/202308:00GLOBEImmutep Quarterly Activities Report
4/26/202310:00GLOBEImmutep Announces Presentation of New TACTI-002 Data at the..
4/26/202308:00GLOBEImmutep Appoints Dr. Florian Vogl as Chief Medical Officer
4/17/202309:00GLOBEImmutep Announces Initiation of Investigator-Initiated Phase..
3/31/202308:00GLOBEImmutep Announces Positive Final Data in 2nd Line Metastatic..
3/30/202308:00GLOBEImmutep Announces Expansion of Triple Combination Therapy in..
3/23/202308:00GLOBEImmutep Announces Abstract Accepted for Mini Oral..
3/14/202308:00GLOBEImmutep Announces Initiation of Phase II/III Trial for..
2/06/202308:00GLOBEImmutep Reaches Enrolment Target for INSIGHT-003 Trial in..
12/28/202218:42VWWhy Did Immutep Ltd Stock Soar Recently?
12/23/202208:40DJNImmutep Has Successful Type C Meeting With FDA

Your Recent History

Delayed Upgrade Clock